AgeX Therapeutics, Inc. (AGE) News

AgeX Therapeutics, Inc. (AGE): $0.97

-0.01 (-1.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AGE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

Filter AGE News Items

AGE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest AGE News From Around the Web

Below are the latest news stories about AgeX Therapeutics Inc that investors may wish to consider to help them evaluate AGE as an investment opportunity.

AgeX Therapeutics Reports Second Quarter 2021 Financial Results

ALAMEDA, Calif., August 13, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021.

Yahoo | August 13, 2021

AgeX Therapeutics and LyGenesis Terminate Merger Negotiations

ALAMEDA, Calif. & PITTSBURGH, July 23, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. ("LyGenesis"), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement. The board of directors of AgeX and the board of directors of LyGenesis each determined that it was in

Yahoo | July 23, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday Morning

Want to get ready for the trading week?

Sarah Smith on InvestorPlace | April 26, 2021

AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and the full year ended December 31, 2020.

Yahoo | March 31, 2021

AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today the online publication of data relating to regeneration, aging, and cancer in bioRxiv. The paper titled "Differential Expression of α, β, and γ Protocadherin Isoforms During Differentiation, Aging, and Cancer" presents for the first time data relating to mechanisms cells may use in the process of regeneration. The paper discloses alterations in certain genes that may prevent regeneration from occurring in adult humans. It also provides evidence that the family of genes may be involved in a wide array of human cancers.

Yahoo | March 12, 2021

AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research collaboration with The Ohio State University using AgeX’s brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism, and cardiac function.

Yahoo | March 10, 2021

AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. ("LyGenesis"), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement for a merger of the two companies. LyGenesis recently received U.S. Food and Drug Administration clearance for its Investigational New Drug application to conduct a Phase 2a clinical trial on the safety, tolerability, and efficacy of its lead cell therapy for patients with end-stage liver disease, with study initiation planned for 2021. The combined company’s pipeline would also include thymus, pancreas, and kidney regeneration, in addition to the existin...

Yahoo | March 2, 2021

AgeX Therapeutics (NYSEMKT:AGE) Shareholders Booked A 40% Gain In The Last Year

Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than...

Yahoo | February 3, 2021

AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE) announced today that due to state and county government health orders, attendance at the AgeX 2020 Annual Meeting of Stockholders (the "Annual Meeting") to be held at 10:00 a.m. Pacific Standard Time on Monday, December 28, 2020 will be permitted only through online participation. The County of Alameda, California, where AgeX’s offices are located and where AgeX had planned to hold the Annual Meeting, has issued Health Officer Order 20-21 (the "Order") restricting or prohibiting many business activities due to the COVID-19 pandemic. The Order provides that offices must close and business must be conducted remotely, except in critical infrastructure sectors where remote work is not possible.

Yahoo | December 22, 2020

Where Do Hedge Funds Stand On AgeX Therapeutics, Inc. (AGE)?

Is AgeX Therapeutics, Inc. (NYSE:AGE) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

Yahoo | November 27, 2020


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6479 seconds.